Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
Zharp2-1
Contact us for more batch information
Zharp2-1
Catalog No. T79600Cas No. 2772600-18-5
Zharp2-1, a RIPK2 inhibitor, inhibits the transcription of inflammatory cytokines induced by MDP-induced or Listeria monocytogenes infection and alleviates MDP-induced peritonitis symptoms in mice, which can be used for the study of inflammatory bowel disease (IBD).
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $62 | In Stock | |
| 10 mg | $98 | In Stock | |
| 25 mg | $196 | In Stock | |
| 50 mg | $322 | In Stock | |
| 100 mg | $513 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Zharp2-1"
LY-364947
Cited
T2048396129-53-6
LY-364947 (HTS466284) is a potent ATP-competitive inhibitor of TGFβR-I.
- $59
Size
QTY
CitedOD36 hydrochloride
T614242387510-88-3
OD36 hydrochloride (OD-36 hydrochloride) is a potent RIPK2 inhibitor with an IC50 of 5.3 nM.OD36 hydrochloride is a macrocyclic inhibitor that binds efficiently to the ATP pocket of the ALK2 kinase and effectively antagonizes mutant ALK2 signaling and osteogenic differentiation.OD36 hydrochloride targets ALK2. OD36 hydrochloride targets ALK2 with a KD of 37 nM.
- $1,290
Size
QTY
RIP1 kinase inhibitor 7
T790442428401-23-2
RIP1 Kinase Inhibitor 7 (Compound 41) serves as a potent inhibitory agent for receptor interacting protein 1 kinase (RIP1) with an IC50 of under 100 nM. Additionally, it demonstrates an EC50 ranging from 1 to 100 nM in cell necrosis assays [1].
- $1,520
Size
QTY
RIPK2/3-IN-1
T79352
RIPK2/3-IN-1 is a potent inhibitor of both RIPK2 and RIPK3 kinases, exhibiting IC50 values of 3 nM for RIPK2 and 117 nM for RIPK3. Additionally, in a 14-TriLAN-Gly/NOD1 THP-1 cell-based NF-κB reporter assay, RIPK2/3-IN-1 demonstrates an IC50 value of 14 ± 4 nM against RIPK2 [1].
- Inquiry Price
Size
QTY
RIPK1-IN-9
T630552682889-57-0In house
RIPK1-IN-9 is a potent and selective inhibitor of RIPK1, a dihydronaphthone compound, which inhibits U937 and L929 cells with an IC50 of 2 nM and 1.3 nM, respectively.
- $360
Size
QTY
Necroptosis-IN-1
T93051391980-92-9In house
Necroptosis-IN-1 is a potent necroptosis inhibitor of RIPK1. It is an analog of Necrostatin-1.
- $96
Size
QTY
GSK2593074A
T114841337531-06-2In house
GSK2593074A (GSK'074) is a programmed necrosis inhibitor that displays inhibitory effects on RIP1 and RIP3.
- $116
Size
QTY
HS-1371
T68152158197-70-5
HS-1371 is a novel kinase inhibitor of receptor-interacting protein kinase 3 (RIP3) with an IC50 of 20.8 nM.
- $48
Size
QTY
GSK3145095
T154371622849-43-7
GSK3145095 is an orally active inhibitor of RIPK1 with IC50 of 5 nM, with potential immunomodulatory activities and antineoplastic.
- $97
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Zharp2-1, a RIPK2 inhibitor, inhibits the transcription of inflammatory cytokines induced by MDP-induced or Listeria monocytogenes infection and alleviates MDP-induced peritonitis symptoms in mice, which can be used for the study of inflammatory bowel disease (IBD). |
| In vitro | iBMDM from mice were stimulated with 10 ng/mL IFN-γ and pre-treated with Zharp2-1 (IC50=6.4-17.4 nM) for 2 hours, followed by stimulation with 10 μg/mL MDP or 1 μg/mL L18-MDP for 12 hours. The results indicate that Zharp2-1 effectively blocks cytokine transcription and release in human and murine cells induced by MDP. [1]. |
| In vivo | Treatment with Zharp2-1 (15 mg/kg, oral gavage, once daily, for 6 days) protects rats from DNBS-induced colon shortening and colon weight gain, indicating that Zharp2-1 therapy significantly improves colonic mucosal structural damage, muscle thickening, and inflammatory infiltration[1]. |
| Molecular Weight | 383.4 |
| Formula | C19H18N3O2PS |
| Cas No. | 2772600-18-5 |
| Storage | store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||
| Solubility Information | DMSO: 2 mg/mL (5.22 mM) | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
| ||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.